Kevin Sharer - Amgen

Kevin Sharer - Amgen
Total Compensation: $18.9 million

Details: After drawing the ire of investors for the company's flagging stock price and steep R&D costs, Sharer is set to retire May 23, after 20 years with Amgen ($AMGN). He took yet another pay cut in 2011, seeing his total compensation fall by more than $2 million, thanks mostly to a more than 50% reduction in option awards from 2010.

Sharer's decade in charge at Amgen saw excellent growth, going from $3.6 billion in revenue to more than $16 billion. However, safety concerns over the company's anemia treatments led to some big losses in the last few years, and the 63-year-old's name has a tendency to pop up on lists of the industry's most overpaid execs. But the news isn't all bad for Sharer. As Dow Jones reported earlier this year, the soon-to-be-ex CEO is likely in line for a $49 million retirement package once he steps down--not William Weldon money, to be sure, but probably enough for some comfortable golden years.

Editor's Note: Sharer's retirement package includes accumulated retirement plan contributions and benefits, and deferred compensation. It also includes stock awards and options.

Kevin Sharer - Amgen
Read more on

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.